Show simple item record

dc.contributor.authorBourdoumis, A
dc.contributor.authorChrisofos, M
dc.contributor.authorStasinou, T
dc.contributor.authorChristopoulos, Panagiotis
dc.contributor.authorMourmouris, P
dc.contributor.authorKostakopoulos, A
dc.contributor.authorDeliveliotis, C
dc.date.accessioned2015-07-01T07:50:28Zen
dc.date.available2015-07-01T07:50:28Zen
dc.date.issued2015-05en
dc.identifier.citationThe role of PCA 3 as a prognostic factor in patients with castration-resistant prostate cancer (CRPC) treated with Docetaxel. 2015, 35 (5):3075-9 Anticancer Resen
dc.identifier.issn1791-7530en
dc.identifier.pmid25964598en
dc.identifier.urihttp://hdl.handle.net/10541/558714en
dc.description.abstractTo investigate potential fluctuations in prostate cancer antigen 3 (PCA 3) scores in castration-resistant prostate cancer (CRPC) patients treated with docetaxel and investigate the assay as a potential prognostic factor.
dc.language.isoenen
dc.rightsArchived with thanks to Anticancer researchen
dc.titleThe role of PCA 3 as a prognostic factor in patients with castration-resistant prostate cancer (CRPC) treated with Docetaxel.en
dc.typeArticleen
dc.contributor.departmentDepartment of Urology, Torbay Hospital, South Devon Healthcare NHS Foundation Trust, Torquayen
dc.identifier.journalAnticancer Researchen
html.description.abstractTo investigate potential fluctuations in prostate cancer antigen 3 (PCA 3) scores in castration-resistant prostate cancer (CRPC) patients treated with docetaxel and investigate the assay as a potential prognostic factor.


This item appears in the following Collection(s)

Show simple item record